Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S. Discover ...

PYZCHIVA becomes Samsung Bioepis’ fifth biosimilar and third immunology biosimilar to be launched in the US Commercialized by Sandoz, PYZCHIVA offers three different strengths Samsung Bioepis Co ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Developed by Samsung Bioepis Co., Ltd., and commercialized by Sandoz, Pyzchiva® has been approved by the US Food and Drug Administration (FDA) for the treatment of certain chronic inflammatory ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...